MEDP Stock Overview
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MEDP from our risk checks.
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Medpace Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$345.18 |
| 52 Week High | US$459.77 |
| 52 Week Low | US$286.76 |
| Beta | 1.36 |
| 1 Month Change | 1.81% |
| 3 Month Change | 5.21% |
| 1 Year Change | 16.40% |
| 3 Year Change | 107.95% |
| 5 Year Change | 289.90% |
| Change since IPO | 1,131.03% |
Recent News & Updates
Here's Why Medpace Holdings (NASDAQ:MEDP) Has Caught The Eye Of Investors
Dec 26
Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
Nov 22Medpace: Buy The Short-Term Pain For Long-Term Gains
Oct 26Recent updates
Here's Why Medpace Holdings (NASDAQ:MEDP) Has Caught The Eye Of Investors
Dec 26Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
Nov 22Medpace: Buy The Short-Term Pain For Long-Term Gains
Oct 26Why Medpace Holdings Is A 'Better Mousetrap'
Oct 16Medpace Holdings, Inc.'s (NASDAQ:MEDP) Earnings Haven't Escaped The Attention Of Investors
Sep 19Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Sep 02Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Aug 20Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem
Jul 31Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Jul 25What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E
Jun 18Medpace: Clear Winner If China Blockade Succeeds
Jun 04A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
May 22Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?
Apr 12Medpace: Exceptional Performance, Almost Fully Priced In
Mar 11Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors
Feb 18Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Feb 09A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jan 25Shareholder Returns
| MEDP | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.0% | 3.4% | 3.8% |
| 1Y | 16.4% | 2.0% | 24.4% |
Return vs Industry: MEDP exceeded the US Life Sciences industry which returned 2% over the past year.
Return vs Market: MEDP underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| MEDP volatility | |
|---|---|
| MEDP Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 9.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MEDP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MEDP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 5,900 | August Troendle | www.medpace.com |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings, Inc. Fundamentals Summary
| MEDP fundamental statistics | |
|---|---|
| Market cap | US$10.78b |
| Earnings (TTM) | US$365.57m |
| Revenue (TTM) | US$2.07b |
29.3x
P/E Ratio5.2x
P/S RatioIs MEDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDP income statement (TTM) | |
|---|---|
| Revenue | US$2.07b |
| Cost of Revenue | US$678.86m |
| Gross Profit | US$1.39b |
| Other Expenses | US$1.03b |
| Earnings | US$365.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 10, 2025
| Earnings per share (EPS) | 11.79 |
| Gross Margin | 67.22% |
| Net Profit Margin | 17.65% |
| Debt/Equity Ratio | 0% |
How did MEDP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 23:01 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medpace Holdings, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Ishan Majumdar | Baptista Research |
| Erin Wilson Wright | Credit Suisse |